Graham Capital Management L.P. Purchases 28,536 Shares of Omnicell, Inc. $OMCL

Key Points

• Graham Capital Management L.P. raised its holdings in Omnicell, Inc. by 76.9%, now owning 65,638 shares valued at approximately $2.3 million.
• Multiple analysts have updated their ratings for Omnicell, with Benchmark dropping their target price from $62 to $40, while Bank of America raised it from $30 to $34.
• Omnicell reported a quarterly earnings per share (EPS) of $0.45, surpassing estimates and reflecting a revenue increase of 5% year-over-year.

Graham Capital Management L.P. raised its position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 76.9% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 65,638 shares of the company's stock after acquiring an additional 28,536 shares during the period. Graham Capital Management L.P. owned approximately 0.14% of Omnicell worth $2,295,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of OMCL. Principal Financial Group Inc. lifted its holdings in shares of Omnicell by 2.6% in the 1st quarter. Principal Financial Group Inc. now owns 244,644 shares of the company's stock worth $8,553,000 after purchasing an additional 6,288 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Omnicell during the first quarter worth $2,073,000. Jane Street Group LLC lifted its stake in shares of Omnicell by 7.4% in the fourth quarter. Jane Street Group LLC now owns 54,282 shares of the company's stock valued at $2,417,000 after buying an additional 3,725 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of Omnicell during the first quarter valued at about $901,000. Finally, XTX Topco Ltd increased its position in shares of Omnicell by 316.1% during the first quarter. XTX Topco Ltd now owns 30,295 shares of the company's stock worth $1,059,000 after acquiring an additional 23,015 shares in the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Stock Performance

NASDAQ:OMCL traded down $1.01 during trading on Friday, reaching $32.11. The company's stock had a trading volume of 423,987 shares, compared to its average volume of 529,548. Omnicell, Inc. has a 12 month low of $22.66 and a 12 month high of $55.74. The firm has a market cap of $1.47 billion, a price-to-earnings ratio of 64.22, a price-to-earnings-growth ratio of 7.01 and a beta of 0.82. The firm has a 50 day moving average of $30.44 and a 200-day moving average of $31.25. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.24 and a current ratio of 1.42.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $0.45 EPS for the quarter, topping analysts' consensus estimates of $0.30 by $0.15. The company had revenue of $290.56 million for the quarter, compared to analysts' expectations of $275.57 million. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The business's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.51 EPS. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. Research analysts expect that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on OMCL. Wells Fargo & Company upped their target price on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a report on Monday, July 21st. Bank of America boosted their price objective on Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a report on Friday, May 23rd. Piper Sandler dropped their target price on Omnicell from $57.00 to $55.00 and set an "overweight" rating on the stock in a report on Monday, August 11th. Finally, Wall Street Zen cut Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $46.71.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.